Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
NCT ID: NCT03283228
Last Updated: 2017-09-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30 participants
OBSERVATIONAL
2017-12-01
2019-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia
NCT01150058
Biomarkers in Young Patients With Acute Myeloid Leukemia
NCT01138332
S9031-S9333-S0112-S0301-A Biomarkers Associated With Response to Cytarabine in Samples From Older Patients With Acute Myeloid Leukemia
NCT01338974
A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
NCT05133882
Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
NCT01005277
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. CD56 antigen expression, an inexpensive, easy to detect and reproduce index, is closely related to the prognosis of AML patients
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CD11b and CD56 markers
Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
Cd11b and Cd56 markers
The expression of CD11b and CD56 in newly diadnosed cases of AML
Haematological parameters in cases of adult AML
Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML
Cd11b and Cd56 markers
The expression of CD11b and CD56 in newly diadnosed cases of AML
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cd11b and Cd56 markers
The expression of CD11b and CD56 in newly diadnosed cases of AML
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. follow up cases of adult AML
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Z A Kamel
Dr
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Myeloid Leukemia Markers
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.